Evidence map›Paper›PMID 42471710›Full record

ArticleJournal of nanobiotechnology2026

A novel nanosensor for in situ detection of EV-miR-107 enables noninvasive tuberculosis diagnosis and treatment monitoring.

Yuan Wu, Shihua Luo, Jin Gu, Wei Xu, Min Yang, Jiayu Zhou, Xiaosai Ma, Chonghai Qiu, Muru Xu, Guixian Huang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuan Wu *MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Qidong-Fudan Innovative Institute of Medical Science, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
Shihua Luo *Center for Clinical Laboratory Diagnosis and Research, Key Laboratory of Research on Clinical Molecular Diagnosis for High Incidence Diseases in Western Guangxi of Guangxi Higher Education Institutions, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, P. R. China.
Jin Gu *Shanghai Clinical Research Center for Infectious Disease (tuberculosis), Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Institute for Advanced Study, Tongji University School of Medicine, Shanghai, 200032, P. R. China.
Wei Xu *MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Qidong-Fudan Innovative Institute of Medical Science, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
Min YangMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Qidong-Fudan Innovative Institute of Medical Science, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
Jiayu ZhouMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Qidong-Fudan Innovative Institute of Medical Science, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
Xiaosai MaMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Qidong-Fudan Innovative Institute of Medical Science, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
Chonghai QiuMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Qidong-Fudan Innovative Institute of Medical Science, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
Muru XuMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Qidong-Fudan Innovative Institute of Medical Science, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China.
Guixian HuangShanghai Clinical Research Center for Infectious Disease (tuberculosis), Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Institute for Advanced Study, Tongji University School of Medicine, Shanghai, 200032, P. R. China.
Liying ZhuShanghai Clinical Research Center for Infectious Disease (tuberculosis), Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Institute for Advanced Study, Tongji University School of Medicine, Shanghai, 200032, P. R. China.
Xunjia ChengMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Qidong-Fudan Innovative Institute of Medical Science, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China. xjcheng@shmu.edu.cn.
Hongbo ShenShanghai Clinical Research Center for Infectious Disease (tuberculosis), Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Institute for Advanced Study, Tongji University School of Medicine, Shanghai, 200032, P. R. China. hbshen@tongji.edu.cn.
Qiliang CaiMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Qidong-Fudan Innovative Institute of Medical Science, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China. qiliang@fudan.edu.cn.
Feifei WangMOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Qidong-Fudan Innovative Institute of Medical Science, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China. wangfeifei@fudan.edu.cn.

Funding

Major Project of Guangzhou National Laboratory GZNL2024A01023National Natural Science Foundation of China Grants 32270972Shanghai Municipal Science and Technology Major Project ZD2021CY001Shanghai Sci-Tech Inno Center for Infection & Immunity SSIII-202415/WB
6 · The paper itself

Abstract

Tuberculosis (TB) remains a leading cause of infectious death globally, creating an urgent need for rapid and non-invasive diagnostics. Extracellular vesicles (EVs) have emerged as promising carriers of disease-specific microRNAs with biomarker potential. This study identifies EV-miR-107 as a candidate host-response biomarker for TB, showing significant upregulation in TB patient plasma and a murine BCG infection model. To utilize this finding, an in-situ detection platform named CLiAN (CHA@Lipo@Aptamer Nanosensor) is developed. It utilizes cationic liposomes functionalized with CD63-specific aptamers and encapsulating catalytic hairpin assembly (CHA) probes to enable targeted EV fusion, facilitating efficient EV miRNA profiling within two hours. Clinically, CLiAN detects EV-miR-107 with 95.2% sensitivity (AUC = 0.87), outperforming sputum culture (36.4%) and Xpert MTB/RIF (54.5%). It also reliably monitors treatment response via dynamic changes in plasma EV-miR-107 levels (p = 0.001), correlating with clinical outcomes. This work establishes an integrated framework for TB management-from biomarker discovery to diagnostics and treatment monitoring-paving the way for improved point-of-care TB control.

Indexed as

Biosensing TechniquesExtracellular VesiclesMicroRNAsTuberculosisAnimalsAptamers, NucleotideBiomarkersHumansLiposomesMiceMycobacterium tuberculosisTetraspanin 30Aptamers, NucleotideBiomarkersLiposomesMicroRNAsMIRN107 microRNA, humanTetraspanin 30Catalytic hairpin assembly (CHA)EV-miR-107 biomarkerExtracellular vesicles (EVs)Liposome-EV fusionTuberculosis diagnosis

Identifiers

PMID42471710
PMCPMC13663235

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.